EMANATE, a global Phase 3 study of setmelanotide across four heterozygous MC4R-pathway genetic subgroups, missed its primary endpoint of percent BMI reduction at 52 weeks in the modified intent-to-treat analysis with prespecified multiple imputation. Placebo-adjusted BMI changes were –4.3% (p=0.15) in POMC/PCSK1 heterozygotes (n=78), –3.6% (p=0.94) in LEPR heterozygotes (n=23), –4.0% (p=0.12) in SRC1/NCOA1 (n=73), and –1.7% (p=0.43) in SH2B1 (n=121). Post hoc analyses using LOCF yielded statistically significant reductions in POMC/PCSK1 (–5.5%; p=0.001) and SRC1 (–6.2%; p<0.0001), with larger effects among Week 52 completers of genetically confirmed cohorts (–9.7% and –8.0%, respectively). Safety was consistent with prior experience, with no new signals. The core development is a setback to Rhythm’s push to broaden setmelanotide’s label beyond existing approvals in BBS and biallelic POMC/PCSK1/LEPR deficiency into more prevalent heterozygous variants. While signals in POMC/PCSK1 and SRC1 subgroups emerge under alternative imputations and completer analyses, they do not rescue the prespecified primary analysis. Rhythm is now pointing development attention to next-generation MC4R agonists, bivamelagon and RM-718, and to genetically defined opportunities highlighted in its DAYBREAK program, including SEMA3, PHIP, TBX3, and PLXNA families. Strategically, the miss crystallizes two tensions. First, methodological: in long, injectable weight-management trials with notable discontinuation risk, the chosen imputation strategy can determine statistical fate. Multiple imputation can be punitive when retention wobbles; LOCF and completer readouts point to drug signal but are unlikely to sway regulators without prospectively aligned methods. Second, biological: heterozygous MC4R-pathway disease is heterogeneous, with variable penetrance and significant noise around variant classification. Rhythm’s emphasis on “true loss-of-function” underscores a likely screen that was not stringent enough on functional validation upfront. The net effect is diluted treatment effect and underpowered subgroup reads, most visible in the small LEPR cohort. For sponsors and CROs working in rare genetic obesity, the takeaway is operational as much as scientific. Eligibility cannot rely on genotype labels alone; centralized functional assays and adjudication at screening are becoming table stakes. Trial designs may need responder run-ins or enrichment by hyperphagia phenotype to stabilize effect size and mitigate placebo response. Retention over 52 weeks with daily injections remains a core risk driver; missing data handling must be harmonized with regulators well before database lock. Sites will need tighter genetics workflows, faster variant curation, and counseling capacity to avoid late exclusions and protocol deviations. Regulators will look for prospectively defined analysis sets tied to functional biology rather than broad heterozygous inclusion, and payers will increasingly benchmark outcomes against GLP-1–based standards now entrenched in obesity care. Next, expect Rhythm to seek Type C feedback on whether any prospectively identifiable subset within POMC/PCSK1 or SRC1 could justify a focused path, but an sNDA anchored on post hoc or completer data is improbable. The more likely course is a rapid pivot of pivotal design to next-generation MC4R agonists with enriched, functionally confirmed populations, potentially incorporating adaptive features, early response gating, and firmer retention scaffolding. Watch for updates on variant adjudication partnerships, incorporation of centralized functional testing as an inclusion criterion, and any head-to-head or add-on strategies relative to GLP-1–based regimens. The unresolved risks are clear: can MC4R agonism deliver reproducible, regulator-acceptable efficacy in heterogeneous heterozygous populations, and can trials be executed with the precision needed to preserve signal in the face of contemporary obesity trial expectations.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
